By continuing to browse the site you are agreeing to our use of cookies and similar tracking technologies described in our privacy policy.

Efficacy and safety of 8-week glecaprevir/pibrentasvir in treatment-naive patients with chronic hepatitis c virus genotype 1, 2, 3, 4, 5, or 6 infection and compensated cirrhosis: EXPEDITION-8 complete results [abstract LP9]

Journal

Presented at Liver Meeting, 2019; November 8-12

Year of Publication

2019

Authors

Type of Article

Conference Proceedings